US2008096855A1PendingUtilityA1
Process for obtaining norelgestromin in different relations of isomers E and Z
Individually held — no corporate assignee on recordPriority: Jun 25, 2003Filed: Dec 18, 2007Published: Apr 24, 2008
Est. expiryJun 25, 2023(expired)· nominal 20-yr term from priority
C07J 41/00
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is related to an oxime of the 13β-ethyl-17α-hydroxi-18,19-dinorpregn-4-en-20-in-3-o (norelgestromin) of Formula I with a relation of isomers E/Z between 1.3 and 1.6 and the method of producing the oxime.
Claims
exact text as granted — not AI-modified1 - 11 . (canceled)
12 . An oxime of the 13β-ethyl-17α-hydroxy-18,19-dinorpregna-4-en-20-yn-3-one (norelgestromin) of Formula I, wherein the oxime of formula I includes isomers E/Z and has a purity between 99.2 to 99.8%.
13 . An oxime of the 13β-ethyl-17α-hydroxi-18,19-dinorpregn-4-en-20-in-3-o (norelgestromin) of Formula I with a relation of isomers E/Z between 1.4-1.6
14 . The oxime according to claim 13 wherein the purity is 99.8%.
15 . The oxime of claim 13 wherein the relation of isomers E/Z is 1.4 and having a purity of 99.2%
16 . The isomer E of norelgestromin according to claim 15 having a purity of 96%.
17 . Norelgestromin with a relation of isomers E/Z between 1.3 to 1.6, when prepared according a process comprising:
a) producing hydroxylamine by adding an acetate salt to a hydroxylamine salt in a solvent medium;
b) adding levonorgestrel to the solution of step a to produce an oxime;
c) adding an acid to modify the acidity of the solution of step b; and
d) adding a base to neutralize the solution.
18 . A pharmaceutical composition comprising:
an oxime of the 13β-ethyl-17α-hydroxi-18,19-dinorpregn-4-en-20-in-3-one (norelgestromin) of Formula I with a relation of isomers E/Z of 1.6 and a purity of 99.8%Join the waitlist — get patent alerts
Track US2008096855A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.